Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.

Baek-Yeol RyooPhilippe MerleAmit S KulkarniAnn-Lii ChengMohamed BouattourHo Yeong LimValeriy BrederJulien EdelineYee ChaoSadahisa OgasawaraThomas YauMarcelo GarridoStephen Lam ChanBruno DanieleJosephine M NorquistErluo ChenAbby B SiegelAndrew X ZhuRichard S FinnMasatoshi Kudo

Published in: Cancer (2020)

Pembrolizumab preserved HRQoL during treatment for advanced HCC. Combined with efficacy and safety results from KEYNOTE-240, these findings support a positive benefit/risk profile for pembrolizumab in a second-line treatment setting for patients with HCC who previously received sorafenib.

Keyphrases

advanced non small cell lung cancer
healthcare
palliative care
phase ii
epidermal growth factor receptor
quality improvement
randomized controlled trial
affordable care act
health insurance
double blind